BioAtla Investor Presentation Deck

Potential market opportunity in metastatic melanoma ~1.3MM ● ~50% people in the U.S. living with melanoma¹ bicatla do not respond to PD-1 therapy in 1L setting² ~100K 30-40% newly diagnosed invasive cases / year (U.S.)¹ initial responders progress² Available Treatment 1L: ICIs 33% - 50% ORR³; (BRAF / Mek inhibitors for BRAF+) 2L+: ICIS 9% -28% ORR (mono - combo, respectively)4 Target population: ~5K ROR2+ addressable 2L+ patients/year in the U.S.1, based on a ROR2 positivity rate of ~10% Internal success threshold: 2L+ ORR of ~20% (approvability bar based on precedent); 25% + (commercially relevant) following BA3011 monotherapy ¹Clarivate, Disease Landscape and Forecast: Malignant Melanoma (2022). www.cancer.net; www.cancer.org; 2Oncology (Williston Park). 33(4):141-8. ³Keytruda USPI accessed June 2022; Opdivo USPI accessed June 2022. 4VanderWalde A, Moon J, Bellasea S, et al. Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy. Presented at: 2022 AACR Annual Meeting; April 8-13, 2022; New Orleans, LA. Abstract CT013. 1L, first line; 2L+, second line or greater; ICIS - Immune checkpoint inhibitors. BioAtla| Overview 27

View entire presentation